To include your compound in the COVID-19 Resource Center, submit it here.

Fast boat to China

Abbisko aims to be first to market in China with ‘me better’ cancer compounds

Abbisko Therapeutics aims to be first-to-market for common cancer indications in China with small molecules against clinically validated targets that are more potent than competing agents in development outside the country.

Abbisko is focusing first on developing therapies against clinically validated targets for indications, like hepatocellular carcinoma (HCC), that are prevalent in China.

“In the beginning, we will work on validated targets that still

Read the full 629 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers